目的: 建立一种稳定且可靠的气相色谱-串联质谱法测定盐酸二甲双胍缓释片中N-亚硝基二甲胺(NDMA),同时通过考察异丙醇和硫代甘油2个添加剂对供试品溶液稳定性的影响,确定了最优的提取条件。方法: 采用聚乙二醇为固定相的AB-InoWax毛细管柱(30 m×0.25 mm×0.25 μm),利用电子轰击电离源(EI),在多反应监测(MRM)模式下检测,分别以外标法和内标法定量。结果: 添加硫代甘油可显著改善供试品溶液稳定性,NDMA在0.25~50 ng·mL-1浓度范围内有良好的线性(r>0.999),方法检测限为0.1 ng·g-1,方法定量限为0.2 ng·g-1,分别在内标法和外标法计算下,平均加标回收率(n=9)均为97.3%和94.9%,精密度、重复性、稳定性及耐用性的RSD均小于8%。对90批次的盐酸二甲双胍缓释片进行检测,结果均小于国家药品监督管理局以及FDA规定的可接受限度的30%之内。结论: 本文建立的方法灵敏度高,专属性强,结果准确且稳定性好,适用于盐酸二甲双胍缓释片中NDMA的定量分析,可为有关产品的质量安全提供技术支撑。
[1] LIU DQ, SUN M, KORD AS. Recent advances in trace analysis of pharmaceutical genotoxic impurities[J]. J Pharm Biomedical Anal, 2010, 51(5): 999
[2] WHITE CM. Understanding and preventing (N-nitrosodimethylamine) NDMA contamination of medications[J]. Annals Pharmacotherapy, 2019, 54(6): 611
[3] 国家药品监督管理局. 世界卫生组织国际癌症研究机构致癌物清单[EB/OL]. https://www.nmpa.gov.cn/xxgk/mtbd/20171030163101383.html
National Medical Products Administration. List of Classifications by Cancer Site[EB/OL]. https://www.nmpa.gov.cn/xxgk/mtbd/20171030163101383.html
[4] Control of Nitrosamine Impurities in Human Drugs[S]. 2021
[5] MILLS AL, ALEXANDERM. N-nitrosamine formation by cultures of several microorganisms[J]. Appl Environ Microb, 1976, 31(6): 892
[6] BUNKAN AJC, HETZLER J, MIKOVINY T, et al. The reactions of N-methylformamide and N,N-dimethylformamide with oh and their photo-oxidation under atmospheric conditions: Experimental and theoretical studies[J]. Phys Chem Chem Phys, 2015, 17(10): 7046
[7] FDA. FDA Requests Removal of All Ranitidine Products (zantac) from the Market[EB/OL]. https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market
[8] 张玉英. 盐酸二甲双胍片的含量测定[J]. 化学世界, 2003, 44(6): 300
ZHANG YY. Determination of metformin tablets by HPLC[J]. Chemical World, 2003, 44(6):300
[9] FDA. FDA Alerts Patients and Health Care Professionals to Nitrosamine Impurity Findings in Certain Metformin Extended-Release Products[EB/OL]. https://www.fda.gov/news-events/press-announcements/fda-alerts-patients-and-health-care-professionals-nitrosamine-impurity-findings-certain-metformin
[10] 吴兆伟, 杜凯, 王琳, 等. GC-MS法测定缬沙坦中的N-亚硝基二甲胺[J]. 中国新药杂志, 2019, 28(20):2478
WU ZW, DU K, WANG L, et al. Determination of the contents of N-nitrosodimethylamine in valsartan by GC-MS[J]. Chin J New Drug, 2019, 28(20):2478
[11] LIU J, XIE B, MAI B, et al. Development of a sensitive and stable GC-MS/MS method for simultaneous determination of four N-nitrosamine genotoxic impurities in sartan substances[J]. J Anal Sci Technol, 2021, 12(1): 3
[12] WICHITNITHAD W, SUDTANON O, SRISUNAK P, et al. Development of a sensitive headspace gas chromatography-mass spectrometry method for the simultaneous determination of nitrosamines in losartan active pharmaceutical ingredients[J]. ACS Omega, 2021, 6(16): 11048
[13] ALSHEHRI YM, ALGHAMDI TS, ALDAWSARI FS. HS-SPME-GC-MS as an alternative method for NDMA analysis in ranitidine products[J]. J Pharm Biomed Anal, 2020, 191: 113582
[14] CHANG SH, HO HY, CHANG CC, et al. Evaluation and optimization of a HS-SPME-assisted GC-MS/MS method for monitoring nitrosamine impurities in diverse pharmaceuticals[J]. J Pharm Biomed Anal, 2022, 221: 115003
[15] SOLANKI R, PATEL C, PATEL R, et al. UHPLC-APCI-TQ-MS analytical method to quantify nitrosamine impurities in the commercial formulation of metformin and glipizide[J]. J Liq Chromatogr R T, 2022: 1
[16] YANG J, MARZAN TA, YE W, et al. A cautionary tale: quantitative LC-HEMS analytical procedures for the analysis of n-nitrosodimethylamine in metformin[J]. AAPS J, 2020, 22(4): 89
[17] KIM H, SUNG D, YU H, et al. Comparison of EI-GC-MS/MS, APCI-LC-MS/MS, and ESI-LC-MS/MS for the simultaneous analysis of nine nitrosamines eluted from synthetic resins into artificial saliva and health risk assessment[J]. Toxics, 2021, 9(10): 230
[18] 景援朝, 王海燕, 孙涛, 等. 基于气相色谱-串联质谱法测定盐酸二甲双胍制剂中基因毒性杂质N-二甲基亚硝胺的质量评价研究[J]. 药物分析杂志, 2022, 42(12):2122
JING YC, WANG HY, SUN T, et al. Quality evaluation of N-ntrosadimethylamine(NDMA) in metformin hydrochloride preparation by gas chromatography tandem mass spectrometry[J]. Chin J Pharm Anal, 2022, 42(12):2122
[19] FRITZSCHE M, BLOM G, KEITEL J, et al. NDMA analytics in metformin products: Comparison of methods and pitfalls[J]. Eur J Pharm Sci, 2022, 168: 106026
[20] EP 11.0[S]. 2023
[21] LIAO X, SHEN L, JIANG Z, et al. NDMA formation during ozonation of metformin: Roles of ozone and hydroxyl radicals[J]. Sci Total Environ, 2021, 796: 149010
[22] JIREŠ J, KALÁŠEK S, GIBALA P, et al. Insight into the formation of N-nitrosodimethylamine in metformin products[J]. J Pharm Biomed Anal, 2021, 195: 113877
[23] BADRAN I, MANASRAH AD, NASSAR NASHAAT N. A combined experimental and density functional theory study of metformin oxy-cracking for pharmaceutical wastewater treatment[J]. RSC Adv, 2019, 9(24): 13403
[24] 叶晓霞, 葛雨琦, 乐健, 等. 缓释制剂辅料导致盐酸二甲双胍降解产生N-亚硝基二甲胺的影响因素研究[J]. 药物分析杂志, 2021, 41(2): 239
YE XX, GE YQ, LE J, et al. Study on influencing factors of metformin hydrochloride’s degradation to N-nitrosodimethylamine inducd by sustained-release excipients[J]. Chin J Pharm Anal, 2021, 41(2):239
[25] HAO G, HU R, WANG X, et al. N-nitrosodimethylamine formation in metformin hydrochloride sustained-release tablets: Effects of metformin and hypromellose used in drug product formulation[J]. J Pharm Biomed Anal, 2023, 222: 115066
[26] NARANG AS, DESAI D, BADAWY S. Impact of excipient interactions on solid dosage form stability[J]. Pharm Res Dordr, 2012, 29(10): 2660
[27] WU Y, LEVONS J, NARANG AS, et al. Reactive impurities in excipients: Profiling, identification and mitigation of drug-excipient incompatibility[J]. AAPS Pharm Sci Tech, 2011, 12(4): 1248
[28] 戴慧旺, 陈建新, 苗笑增, 等. 醇类对UV-Fenton体系羟基自由基淬灭效率的影响[J]. 中国环境科学, 2018, 38(1): 202
DAI HW, CHEN JX, MIAO XZ, et al. Effect of alcohols on scavenging efficiencies to hydroxyl radical in UV-Fenton system[J]. China Environ Sci, 2018, 38(1):202
[29] WANG L, LI B, DIONYSIOU DD, et al. Overlooked formation of H2O2 during the hydroxyl radical-scavenging process when using alcohols as scavengers[J]. Environ Sci Technol, 2022, 56(6): 3386
